	US 11,839,595 B2
	Mirdametinib treatment
Uchenna H Iloeje, Stamford, CT (US); Abraham J Langseth, Stamford, CT (US); and Todd Shearer, Stamford, CT (US)
Assigned to SPRINGWORKS THERAPEUTICS, INC., Stamford, CT (US)
Filed by SpringWorks Therapeutics Inc., Stamford, CT (US)
Filed on Mar. 20, 2023, as Appl. No. 18/186,312.
Application 18/186,312 is a continuation of application No. 18/185,148, filed on Mar. 16, 2023.
Claims priority of provisional application 63/321,036, filed on Mar. 17, 2022.
Claims priority of provisional application 63/321,046, filed on Mar. 17, 2022.
Prior Publication US 2023/0293466 A1, Sep. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/166 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01)

CPC A61K 31/166 (2013.01) [A61K 9/0053 (2013.01); A61P 35/00 (2018.01)]

26 Claims

1. A method of treating a human patient 2 years or older who has neurofibromatosis type 1 (NF1) associated inoperable plexiform neurofibromas (PN) comprising orally administering an effective amount of mirdametinib to the patient, wherein an amount of mirdametinib is administered on the first day of treatment to provide a C_maxno more than 40 ng/mL.